PALO ALTO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Affymax, Inc. , a biopharmaceutical company, today announced that Arlene M. Morris, the company's president and chief executive officer, will present at the 9th Annual BIO CEO & Investor Conference on Monday, February 12, at 2:00 p.m. Eastern Time at The Waldorf-Astoria Hotel in New York.
A live webcast of the presentation will be available on the Investors section of the company's website at www.affymax.com. A replay will also be available for 30 days following the presentation.
About Affymax, Inc.
Affymax, Inc. is a biopharmaceutical company developing novel peptide- based drugs to improve the treatment of serious and often life-threatening conditions. Affymax's lead product candidate, Hematide(TM), is currently in Phase 2 clinical trials for the treatment of anemia associated with chronic kidney disease and cancer.
Affymax, Inc.CONTACT: Sylvia Wheeler, Executive Director, Investor Relations ofAffymax, Inc., +1-650-812-8861; or media, Jani Bergan, Senior Associate ofWeissComm Partners, +1-415-946-1064, for Affymax, Inc.
Web site: http://www.affymax.com//
